There has been an explosion of interest in glucagon-like peptide1 receptor agonists (GLP-1 RAs or GLP-1s) not only for blood sugar control in diabetes, but for other metabolic conditions such as obesity and arthritis. Like other medications, care needs to be taken to rely on medication, alone, for managing these conditions. GLP-1 receptors are not without potential side effects and risks. Let’s explore the current evidence for them as they relate particularly to blood sugar and weight control. What are…
